| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From The Clinical Research Centers |
Program in Neuroscience, Harvard Medical School (J.M.Z., C.A.C.), and Circadian, Neuroendocrine, and Sleep Disorders Section, Endocrine Division, Department of Medicine, Harvard Medical School, Brigham and Womens Hospital (J.M.Z., S.A.S., C.A.C.), Boston, Massachusetts 02115; and Pulmonary and Critical Care Medicine Section, Spinal Cord Injury Service, Brockton/West Roxbury Veterans Administration Medical Center (N.T.A., R.B.), West Roxbury, Massachusetts 02132
Address all correspondence and requests for reprints to: Dr. Charles A. Czeisler, Circadian, Neuroendocrine, and Sleep Disorders Section, Endocrine Division, Department of Medicine, Harvard Medical School, Brigham and Womens Hospital, 221 Longwood Avenue, Room 438A, Boston, Massachusetts 02115. E-mail: caczeisler{at}gcrc.bwh.harvard.edu
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
|
| Subjects and Methods |
|---|
|
|
|---|
We studied five male, chronic SCI subjects (see Table 1
for characteristics) in a 4-day
in-patient study. The level of the spinal cord injury was determined by
neurological examination. Three of these subjects had neurologically
complete (Frankel A) cervical injuries, and two had similarly complete
thoracic injuries. Besides the neurological damage to their spinal
cords, each subject was physically and mentally healthy, as determined
by history and physical examination, psychological questionnaires (Beck
Depression Inventory, Minnesota Multiphasic Personality Inventory II)
and interview with a psychologist, electrocardiogram, blood and urine
chemistries, and chest radiographs. In no case was brain damage or
extended loss of consciousness associated with the SCI. All subjects
gave their written informed consent to participate in the protocol,
which was approved by the Brigham and Womens Hospital human research
committee. Except as noted in Table 1
, all subjects were drug free at
the time of study, including prescription, nonprescription, and over
the counter medications, as well as caffeine, nicotine,
and alcohol, as confirmed by urine toxicology on the first day of the
in-patient study. During the week before the study, subjects maintained
a regular sleep/wake schedule, as confirmed by wrist actigraphy and
self-report. Subjects entered the laboratory on the morning of day
1.
|
For the duration of the 4-day in-patient study, subjects
remained individually in rooms free from time cues (i.e.
sound attenuation, no windows, no radio, no television, no information
sources as to the time of day) and had regular contact with the
technical and nursing staff. Day 1 was spent in ordinary indoor room
light (
150 lux) relaxing, watching videos, and orienting to the
laboratory and testing procedures. Subjects were scheduled for bed in
total darkness (<0.03 lux) for 8 h, with the timing of their
laboratory sleep episode established by averaging the bed times and
wake times during the week before entry and scheduling the average
midpoint of their at-home nightly sleep episode to be the midpoint of
their scheduled sleep in the laboratory. Upon awakening on day 2,
subjects began 46 h of enforced wakefulness in a constant
semirecumbent posture referred to as a constant routine (31, 32, 33). The
purpose of this procedure was to eliminate or hold constant variables
that might otherwise mask the output of the circadian timing system. In
short, subjects remained in bed throughout the constant routine, with
the lower half of the bed horizontal and the head of the bed elevated
to approximately 35°. Lights were kept dim (<10 lux), and room
temperature remained stable, as did the number of blankets that covered
the subject. Meals and fluids were given in equal, hourly aliquots,
such that each subject received the same amount of fluid, nutrition,
and calories during any 24-h period of the constant routine as they
would have on a baseline day. A staff member was continuously present
in the room with the subject during the constant routine to ensure
compliance with the protocol. To reduce the risk of pressure sores,
every 2 h subjects were allowed to change the side of their body
on which they were lying. Furthermore, if necessary, bowel care was
performed in bed during the first 5 h of the constant routine, and
any medications were given at regularly scheduled intervals, as
indicated in Table 1
.
During h 4244 of the constant routine, subjects were exposed to brighter (>600 lux) light, after which time they returned to the dim light condition for the final 2 h. Light exposure of this intensity has been previously shown to evoke an acute decrease in otherwise elevated nocturnal plasma melatonin concentrations in able-bodied subjects (34, 35). It has been shown that photic suppression of plasma melatonin is likely to indicate an intact eye to SCN to pineal pathway in humans (36). After the 46-h constant routine, subjects were allotted an 8-h sleep episode in darkness, after which time they were medically examined and cleared for discharge.
Physiological monitoring
Blood was collected from an indwelling, iv forearm catheter one to three times each hour, beginning on the afternoon of day 1 or upon awakening on day 2. The plasma was collected, frozen, and later assayed for melatonin (RIA; sensitivity of 5 pg/mL; intra- and interassay coefficients of variation, 8% and 13%, respectively; DiagnosTech, Osceola WI) (37, 38), cortisol (chemiluminescent assay; sensitivity, 0.26 µg/dL; intra- and interassay coefficients of variation, 7% and 10%, respectively), and TSH (chemiluminescent assay; sensitivity, 0.006 µIU/mL; intra- and interassay coefficients of variation, 17% and 5%, respectively). Body and skin temperature, urine volume and content, cardiovascular function, electroencephalography, and neurobehavioral performance test data were also collected during the protocol, although they are not discussed herein.
Additional comparison groups
Two historical groups of able-bodied controls, both previously studied in our laboratory, were used for endocrinological comparisons. One group, previously reported by Allan and Czeisler (5), provided normative data against which to compare the TSH rhythm in the SCI subjects (n = 14). Differences between the current experimental protocol and that of this comparison group were that the latter had 2 baseline days before the constant routine instead of 1, and the constant routine had an ambient illumination of about 150 lux. The second comparison group (n = 24), reported by Zeitzer (35), provides normative data against which to compare the rhythms of melatonin and cortisol. Differences between the current experimental protocol and that of this comparison group are that the latter had 3 baseline days before the constant routine instead of 1 and also had 2 weeks of a regular sleep/wake history before study entry instead of 1 week. Identical assays were performed on the samples collected from control and experimental groups.
Hormone analyses
For TSH, melatonin, and cortisol, up to three parameters were calculated for each subject: 24-h average, circadian amplitude, and circadian timing (phase). For each of the three hormones, the 24-h average was defined as the average of the values between h 5 and 29 of the constant routine. The first 5 h were excluded so as to reduce any influence of sleep or the small postural change (from supine to semirecumbent) that occurred at the beginning of the constant routine. The circadian amplitude and phase of cortisol were estimated by fitting a sine wave, with a period of 24 h, to data from h 542 of the constant routine. The sine wave that best fit the data was calculated using a nonlinear least squares fitting analysis based upon the Levenberg-Marquardt method (CurveExpert, version 1.34; D Hyams, Starkville, MS). The peak of the fitted sine wave was used as the marker of the phase of the rhythm, and half the distance between the peak and the trough of the fitted sine wave was used as the measure of rhythm amplitude. The circadian phase and amplitude of the TSH rhythm were estimated by fitting a sine wave, with a period of 24 h, to data from h 529 of the constant routine so as to reduce the residual effects of the prior sleep episode and the ongoing sleep deprivation on TSH secretion (5). The onset of TSH secretion was used as the marker of the phase of the rhythm and was determined by calculating the time at which the fitted curve rose to 25% of twice the amplitude (nadir + 25% of the peak to trough value) (39). Half the distance between the peak and the trough of the sine wave was used as a measurement of circadian amplitude. The circadian phase of melatonin was determined by calculating the midpoint between the time at which plasma melatonin concentrations first rose above the 24-h average and the time at which the plasma melatonin concentration first dropped below the 24-h average (midpoint of the upward and downward mean crossings) (35, 40, 41).
The suppression of plasma melatonin in response to the 2-h bright light
exposure during h 4244 of the constant routine was calculated as:
![]() |
It has been previously demonstrated that the timings of physiological
variables influenced by the SCN have typical phase relationships with
the sleep/wake and dark/light schedule to which an individual is
exposed (1, 2, 3, 5, 8, 42, 43). As such, to determine whether
relationships were normal in individuals with SCI, we calculated the
phase angle (
) between typical bedtime and TSH onset as well as that
between typical waketime and both melatonin midpoint and cortisol
maximum. The normalcy of these phase angles as well as the hormone
amplitude data were evaluated by averaging across the subjects in the
comparison groups, calculating a SD, and determining the
95% confidence intervals, then comparing the individual SCI subjects
to these intervals.
| Results |
|---|
|
|
|---|
Plasma melatonin concentrations in the tetraplegic subjects were
near or below the lower limit of assay sensitivity, thereby exhibiting
no observable rhythmicity and precluding calculation of a 24-h average,
melatonin phase, and melatonin suppression in these three subjects
(Fig. 2
). In contrast, both paraplegic
subjects (T4A and T5A) exhibited normal melatonin rhythmicity. The 24-h
average of plasma melatonin concentration and phase angle between the
midpoint of the melatonin peak and typical bedtime in both paraplegic
subjects were within the 95% confidence limits of the able-bodied
comparison subjects (i.e. normal) (Table 2
). Also, in these two paraplegic
subjects the plasma melatonin concentration was suppressed by the
2 h of nocturnal light exposure at the end of the constant routine
(T4A, 62.5% suppressed; T5A, 42.9% suppressed), consistent with the
response observed in able-bodied subjects (34, 35). Such a response
indicates an intact sympathetic innervation of the pineal gland.
|
|
In contrast to melatonin, rhythmic production of cortisol
appeared intact in each of the five SCI subjects (Fig. 3
). The average 24-h plasma concentration
profile and circadian amplitude of all five SCI subjects were within
the 95% confidence limits of the able-bodied comparison subjects
(Table 2
). The phase angle between the fitted maximum of cortisol
secretion and typical waketime was normal in four of the five SCI
subjects (Table 2
). Plasma cortisol concentrations during the 2 h
of brighter nocturnal light exposure at the end of the constant routine
appeared to decline in four of the five SCI subjects, although more
subjects would be required to determine the reliability of this
observation.
|
Results from the analysis of TSH were similar to those of cortisol
(Fig. 4
). The average 24-h concentration
in four of the five SCI subjects was normal (Table 2
). However, though
the average 24-h concentration in only one of the SCI subjects was
beyond the 95% confidence limits of the able-bodied comparison
subjects, the other four SCI subjects were on the low end of the normal
range of TSH secretion. The phase angle between TSH onset and typical
bedtime was normal in four of the five SCI subjects, with the same
subject who displayed an abnormally early cortisol phase also having an
abnormally early TSH phase (Table 2
). The circadian amplitude was
normal in four of the five SCI subjects, although a different subject
had a lower circadian amplitude than the subject with the significantly
low 24-h average (Table 2
). As with the able-bodied subjects, there
were no consistent responses to the brighter light exposure in the TSH
pattern of any of the patients.
|
| Discussion |
|---|
|
|
|---|
In contrast to the disruption of the melatonin circuit, the neurohumoral influence of the hypothalamus on cortisol and TSH production remains intact in SCI, although the spinal influences on the adrenal cortex that convey information about acute environmental changes may be disrupted. Previous studies have provided conflicting data on the normalcy of cortisol amplitude in chronic SCI, with some claiming low, others claiming normal, and yet others claiming high circulating concentrations of cortisol or its metabolite 17-hydroxycorticosteroid in such individuals (12, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 29, 30). However, those studies generally relied upon one or two time points in the determination of amplitude. Under such circumstances, the daily rhythmicity of cortisol concentrations and its inherent pulsatility may have confounded the results. Our study, which employed a frequent blood-sampling protocol (three times per h for 24 h) during a constant routine, demonstrated that both the 24-h average and the circadian amplitude of the cortisol rhythm in our SCI subjects were indistinguishable from those in the able-bodied subjects, even among tetraplegics who lacked melatonin.
The literature concerning basal TSH production in chronic SCI is far less extensive than that concerning cortisol. The few studies that have examined TSH have each reported normal plasma concentrations in chronic SCI subjects (14, 18, 19, 27, 28). However, as with much of the cortisol literature, those studies have relied upon a single morning sample in the determination of TSH concentration. TSH also displays a daily rhythmicity, and, as with cortisol, examination of a single time point is insufficient to assess the 24-h profile. In accounting for this variation as well as the suppressive effects of sleep on TSH production, our study has shown that the 24-h average and the circadian amplitude of the TSH rhythm in the chronic SCI subjects were within the low end of the normal range. Whether there actually is a small decline in TSH amplitude in chronic SCI remains a question for further study in a larger sample of subjects.
It has been suggested that melatonin can affect the amplitude of the secretion of TSH and cortisol (45, 46). However, our observation of normal TSH and cortisol amplitudes in the absence of melatonin secretion implies that such an effect is small or absent in humans, assuming that there are no long term compensatory changes. Furthermore, the presence of rhythmic TSH and cortisol in the absence of rhythmic melatonin indicates that pineal melatonin secretion is not necessary to drive these rhythms.
The circadian timing system regulates the oscillation and temporal organization of many biological functions. It has been postulated that the pineal neurohormone melatonin may play a role in the coupling of these downstream rhythms (47), possibly through direct feedback onto the melatonin receptors in the SCN (48, 49) or indirectly by its hypothermic (50) or somnogenic effects (51). We examined the potential role of melatonin in coupling these rhythms by evaluating the phase angles between cortisol, TSH, and sleep in the presence (paraplegics) and absence (tetraplegics) of melatonin. In the two paraplegic subjects, the timing of each of the three hormones was normally aligned with respect to the sleep/wake pattern. In two of the three tetraplegics, the rhythms of cortisol and TSH were normally timed with respect to the sleep/wake pattern. In the third (C6/C7A), the timing of the rhythms of both cortisol and TSH were phase advanced relative to the sleep episode (i.e. the onset of TSH and the peak of cortisol occurred earlier than would have been predicted by the subjects sleep/wake times). This could be a random, anomalous result, a possibility difficult to exclude given our small sample size and the observation of such anomalies among able-bodied subjects (52). Alternatively, if data from a larger study were to indicate that it was probable that the rhythms of TSH and cortisol were truly out of phase with the sleep/wake cycle in some tetraplegics compared to those in paraplegics, it would support the hypothesis that melatonin could act as a coupling agent for SCN-controlled variables. This hypothesis may receive further support in the continued examination of the high prevalence of nonapnea-related sleep disturbances in SCI patients (53).
Using the rigorously controlled, constant routine protocol to examine circadian variation in endocrine function, we demonstrated that patients with neurologically complete injury to the lower cervical spinal cord do not produce melatonin. This further indicates that any parasympathetic or direct innervation of the pineal by the pretectum is insufficient to generate significant melatonin secretion in humans. Those subjects with neurologically complete injury to the upper thoracic spinal cord had normal melatonin rhythmicity. Our data also indicate that the long-term loss of melatonin or a substantial amount of peripheral somatic sensory information does not result in substantial changes in the quantitative or temporal characteristics of cortisol or TSH.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Present address: Department of Neurology, University of California
School of Medicine, Los Angeles, California 90095. ![]()
Received November 23, 1999.
Revised February 18, 2000.
Accepted March 11, 2000.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J. Arendt Melatonin: Characteristics, Concerns, and Prospects J Biol Rhythms, August 1, 2005; 20(4): 291 - 303. [Abstract] [PDF] |
||||
![]() |
H. S. Lecamwasam, H. A. Baboolal, and P. F. Dunn Acute Adrenal Insufficiency After Large-Dose Glucocorticoids for Spinal Cord Injury Anesth. Analg., December 1, 2004; 99(6): 1813 - 1814. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |